Search
Lepu Medical Receives Approval for Clinical Trial of Recombinant Botulinum Toxin Type A Injection
1 week ago /
Read about 0 minute
Author：小编
Lepu Medical's subsidiary, Lepu Jiantang Pharmaceutical, has secured approval from the National Medical Products Administration to initiate clinical trials for its in-house developed recombinant botulinum toxin type A injection. This product stands out with its low biological risk and high purity, further bolstering Lepu Medical's research and development capabilities as well as its product portfolio in the dermatology sector. Nevertheless, subsequent R&D endeavors entail risks including high uncertainty in clinical trial outcomes, substantial investments, and extended timelines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
